Needham Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia reiterates a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintains a $21 price target.
June 05, 2023 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Cogent Biosciences and maintains a $21 price target.
The reiteration of a Buy rating and maintenance of a $21 price target by Needham analyst Ami Fadia indicates a positive outlook for Cogent Biosciences. This news is directly related to the company and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100